NEW YORK (GenomeWeb) – Curetis announced today that it has signed a three-year deal making Swiss services firm Axon Labs the exclusive distributor of its Unyvero molecular diagnostic products in Central and Eastern Europe nations including Austria, the Czech Republic, Slovakia, Slovenia, and Croatia.
The arrangement includes contractual minimum purchase commitments by Axon Labs. Additional terms were not disclosed.
"We are excited to partner with Curetis for the commercial distribution of the Unyvero platform with all of its current and future application cartridges in several of our core markets in Europe," Guido Mueller, Axon Labs general manager for Austria, said in a statement.
"We expect that the Axon Lab partnership will allow us to accelerate the commercial roll-out of Unyvero products in smaller markets, such as Austria, while adding several new markets to our distribution portfolio," Curetis Chief Commercial Officer Achim Plum added. "Moreover, the agreement allows us to focus our direct commercial efforts on the largest Western European markets such as the UK, France, Benelux, and Germany, as well as Switzerland, to drive our growth."
Curetis has signed a number of distribution agreements for its Unyvero products recently.
In October, the company named Acumen Research Laboratories as the exclusive distributor of the Unyvero line in countries that are part of the Association of Southeast Asian Nations. The month before, it inked a deal making Beijing Clear Biotech the exclusive Unyvero distributor in China, Hong Kong, and Taiwan.
It has also signed distribution agreements for Italy and the Middle East with Arrow Diagnostics and Al Zahrawi Medical, respectively.